Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 1|pp. 450–459
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
Back to articleFigure 3(3 of 8)
100%
Figure 3
Figure 3.Forest plot comparing PFS for talazoparib, olaparib, and TPC.
Figure 3 — Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis | Aging